Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021
Abstract Background The coronavirus disease 2019 (COVID-19) vaccines can cause adverse events that can lead to vaccine hesitancy. This study aims at estimating the prevalence of severe adverse events (SAEs) and their associated factors among health professionals vaccinated with ChAdOx1 nCoV-19 vacci...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
BMC
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/fec35a3e3ec44844bfc446666a8569a2 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:fec35a3e3ec44844bfc446666a8569a2 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:fec35a3e3ec44844bfc446666a8569a22021-11-28T12:13:18ZPrevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 202110.1186/s13690-021-00741-x2049-3258https://doaj.org/article/fec35a3e3ec44844bfc446666a8569a22021-11-01T00:00:00Zhttps://doi.org/10.1186/s13690-021-00741-xhttps://doaj.org/toc/2049-3258Abstract Background The coronavirus disease 2019 (COVID-19) vaccines can cause adverse events that can lead to vaccine hesitancy. This study aims at estimating the prevalence of severe adverse events (SAEs) and their associated factors among health professionals vaccinated with ChAdOx1 nCoV-19 vaccine in Togo. Methods A cross-sectional study was conducted from March 13th to 19th, 2021 in Togo among health professionals who received the first dose of the vaccine. An online self-administered questionnaire was used to collect sociodemographic and vaccination data. SAEs were defined as one resulting in hospitalization, medical consultation, or inability to work the day following the administration of the vaccine. Data analysis were performed using R© 4.0.1 software, and a 5% significance level was considered. Results A total of 1,639 health professionals (70.2% male) with a median age of 32 (interquartile range: 27-40) were enrolled. At least one adverse event was reported among 71.6% of participants (95% CI = [69.3-73.8]). The most commonly reported adverse events were injection site pain (91.0%), asthenia (74.3%), headache (68.7%), soreness (55.0%), and fever (47.5%). An increased libido was also reported in 3.0% of participants. Of the participants who experienced adverse events, 18.2% were unable to go to work the day after vaccination, 10.5% consulted a medical doctor, and 1.0% were hospitalized. The SAEs’ prevalence was 23.8% (95% CI = [21.8-25.9]). Being <30 years (AOR = 5.54; p<0.001), or 30-49 years (AOR = 3.62; p<0.001) and being female (AOR = 1.97; p<0.001) were associated with SAEs. Conclusions High prevalence of SAEs have been observed in health professionals in Togo after ChAdOx1 nCoV-19 vaccination especially in young people and females. However, these data are reassuring as they inform on COVID-19 vaccines’ SAE management. Systematic prescription of antalgics or antipyretics could be proposed to young people who get vaccinated.Yao Rodion KonuFifonsi Adjidossi Gbeasor-KomlanviMouhoudine YerimaArnold Junior SadioMartin Kouame TchankoniWendpouire Ida Carine Zida-CompaoreJosée Nayo-ApetsianyiKossivi Agbélénko AfanviSibabe AgoroMounerou SalouDadja Essoya LandohAtany B. NyansaEssohanam BokoMoustafa MijiyawaDidier Koumavi EkoueviBMCarticleAdverse eventChAdOx1 nCoV-19COVID-19VaccineHealth professionalsTogoPublic aspects of medicineRA1-1270ENArchives of Public Health, Vol 79, Iss 1, Pp 1-9 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Adverse event ChAdOx1 nCoV-19 COVID-19 Vaccine Health professionals Togo Public aspects of medicine RA1-1270 |
| spellingShingle |
Adverse event ChAdOx1 nCoV-19 COVID-19 Vaccine Health professionals Togo Public aspects of medicine RA1-1270 Yao Rodion Konu Fifonsi Adjidossi Gbeasor-Komlanvi Mouhoudine Yerima Arnold Junior Sadio Martin Kouame Tchankoni Wendpouire Ida Carine Zida-Compaore Josée Nayo-Apetsianyi Kossivi Agbélénko Afanvi Sibabe Agoro Mounerou Salou Dadja Essoya Landoh Atany B. Nyansa Essohanam Boko Moustafa Mijiyawa Didier Koumavi Ekouevi Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021 |
| description |
Abstract Background The coronavirus disease 2019 (COVID-19) vaccines can cause adverse events that can lead to vaccine hesitancy. This study aims at estimating the prevalence of severe adverse events (SAEs) and their associated factors among health professionals vaccinated with ChAdOx1 nCoV-19 vaccine in Togo. Methods A cross-sectional study was conducted from March 13th to 19th, 2021 in Togo among health professionals who received the first dose of the vaccine. An online self-administered questionnaire was used to collect sociodemographic and vaccination data. SAEs were defined as one resulting in hospitalization, medical consultation, or inability to work the day following the administration of the vaccine. Data analysis were performed using R© 4.0.1 software, and a 5% significance level was considered. Results A total of 1,639 health professionals (70.2% male) with a median age of 32 (interquartile range: 27-40) were enrolled. At least one adverse event was reported among 71.6% of participants (95% CI = [69.3-73.8]). The most commonly reported adverse events were injection site pain (91.0%), asthenia (74.3%), headache (68.7%), soreness (55.0%), and fever (47.5%). An increased libido was also reported in 3.0% of participants. Of the participants who experienced adverse events, 18.2% were unable to go to work the day after vaccination, 10.5% consulted a medical doctor, and 1.0% were hospitalized. The SAEs’ prevalence was 23.8% (95% CI = [21.8-25.9]). Being <30 years (AOR = 5.54; p<0.001), or 30-49 years (AOR = 3.62; p<0.001) and being female (AOR = 1.97; p<0.001) were associated with SAEs. Conclusions High prevalence of SAEs have been observed in health professionals in Togo after ChAdOx1 nCoV-19 vaccination especially in young people and females. However, these data are reassuring as they inform on COVID-19 vaccines’ SAE management. Systematic prescription of antalgics or antipyretics could be proposed to young people who get vaccinated. |
| format |
article |
| author |
Yao Rodion Konu Fifonsi Adjidossi Gbeasor-Komlanvi Mouhoudine Yerima Arnold Junior Sadio Martin Kouame Tchankoni Wendpouire Ida Carine Zida-Compaore Josée Nayo-Apetsianyi Kossivi Agbélénko Afanvi Sibabe Agoro Mounerou Salou Dadja Essoya Landoh Atany B. Nyansa Essohanam Boko Moustafa Mijiyawa Didier Koumavi Ekouevi |
| author_facet |
Yao Rodion Konu Fifonsi Adjidossi Gbeasor-Komlanvi Mouhoudine Yerima Arnold Junior Sadio Martin Kouame Tchankoni Wendpouire Ida Carine Zida-Compaore Josée Nayo-Apetsianyi Kossivi Agbélénko Afanvi Sibabe Agoro Mounerou Salou Dadja Essoya Landoh Atany B. Nyansa Essohanam Boko Moustafa Mijiyawa Didier Koumavi Ekouevi |
| author_sort |
Yao Rodion Konu |
| title |
Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021 |
| title_short |
Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021 |
| title_full |
Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021 |
| title_fullStr |
Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021 |
| title_full_unstemmed |
Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021 |
| title_sort |
prevalence of severe adverse events among health professionals after receiving the first dose of the chadox1 ncov-19 coronavirus vaccine (covishield) in togo, march 2021 |
| publisher |
BMC |
| publishDate |
2021 |
| url |
https://doaj.org/article/fec35a3e3ec44844bfc446666a8569a2 |
| work_keys_str_mv |
AT yaorodionkonu prevalenceofsevereadverseeventsamonghealthprofessionalsafterreceivingthefirstdoseofthechadox1ncov19coronavirusvaccinecovishieldintogomarch2021 AT fifonsiadjidossigbeasorkomlanvi prevalenceofsevereadverseeventsamonghealthprofessionalsafterreceivingthefirstdoseofthechadox1ncov19coronavirusvaccinecovishieldintogomarch2021 AT mouhoudineyerima prevalenceofsevereadverseeventsamonghealthprofessionalsafterreceivingthefirstdoseofthechadox1ncov19coronavirusvaccinecovishieldintogomarch2021 AT arnoldjuniorsadio prevalenceofsevereadverseeventsamonghealthprofessionalsafterreceivingthefirstdoseofthechadox1ncov19coronavirusvaccinecovishieldintogomarch2021 AT martinkouametchankoni prevalenceofsevereadverseeventsamonghealthprofessionalsafterreceivingthefirstdoseofthechadox1ncov19coronavirusvaccinecovishieldintogomarch2021 AT wendpouireidacarinezidacompaore prevalenceofsevereadverseeventsamonghealthprofessionalsafterreceivingthefirstdoseofthechadox1ncov19coronavirusvaccinecovishieldintogomarch2021 AT joseenayoapetsianyi prevalenceofsevereadverseeventsamonghealthprofessionalsafterreceivingthefirstdoseofthechadox1ncov19coronavirusvaccinecovishieldintogomarch2021 AT kossiviagbelenkoafanvi prevalenceofsevereadverseeventsamonghealthprofessionalsafterreceivingthefirstdoseofthechadox1ncov19coronavirusvaccinecovishieldintogomarch2021 AT sibabeagoro prevalenceofsevereadverseeventsamonghealthprofessionalsafterreceivingthefirstdoseofthechadox1ncov19coronavirusvaccinecovishieldintogomarch2021 AT mounerousalou prevalenceofsevereadverseeventsamonghealthprofessionalsafterreceivingthefirstdoseofthechadox1ncov19coronavirusvaccinecovishieldintogomarch2021 AT dadjaessoyalandoh prevalenceofsevereadverseeventsamonghealthprofessionalsafterreceivingthefirstdoseofthechadox1ncov19coronavirusvaccinecovishieldintogomarch2021 AT atanybnyansa prevalenceofsevereadverseeventsamonghealthprofessionalsafterreceivingthefirstdoseofthechadox1ncov19coronavirusvaccinecovishieldintogomarch2021 AT essohanamboko prevalenceofsevereadverseeventsamonghealthprofessionalsafterreceivingthefirstdoseofthechadox1ncov19coronavirusvaccinecovishieldintogomarch2021 AT moustafamijiyawa prevalenceofsevereadverseeventsamonghealthprofessionalsafterreceivingthefirstdoseofthechadox1ncov19coronavirusvaccinecovishieldintogomarch2021 AT didierkoumaviekouevi prevalenceofsevereadverseeventsamonghealthprofessionalsafterreceivingthefirstdoseofthechadox1ncov19coronavirusvaccinecovishieldintogomarch2021 |
| _version_ |
1718408177584701440 |